These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2547256)

  • 1. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection.
    Metselaar HJ; Rothbarth PH; Brouwer RM; Wenting GJ; Jeekel J; Weimar W
    Transplantation; 1989 Aug; 48(2):264-6. PubMed ID: 2547256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.
    Balk AH; Weimar W; Rothbarth PH; Meeter K; Metselaar HJ; Mochtar B; Simoons ML
    Infection; 1993; 21(4):195-200. PubMed ID: 8225620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus infection and renal transplantation.
    Metselaar HJ; Weimar W
    J Antimicrob Chemother; 1989 Jun; 23 Suppl E():37-47. PubMed ID: 2550411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
    N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin.
    Metselaar HJ; Balk AH; Mochtar B; Rothbarth PH; Weimar W
    Chest; 1990 Feb; 97(2):396-9. PubMed ID: 2153508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C
    Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of CMV infection by screening for CMV antibodies in renal allograft recipients and their blood and kidney donors.
    Metselaar HJ; Ploeg RJ; Van Loon AM; Weiland HT; Rothbarth PH; Paul LC; Brand A; Schaafsma R; Hendriks GF; Jeekel J
    Scand J Infect Dis; 1988; 20(2):135-9. PubMed ID: 2840730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frequency of infection with cytomegaloviruses (CMV) following kidney transplantation and initial experiences with CMV gamma globulin prevention].
    Kaden J; Scholz D; Eichler C; May G
    Immun Infekt; 1985 Nov; 13(6):290-5. PubMed ID: 3000922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally produced specific cytomegalovirus immunoglobulin for intramuscular use as a therapy in renal allograft recipients.
    Trkuljić M; Ignjatović L; Hrvacević R; Taseski J; Dujić A; Jovanović D; Kuljić-Kapulica N
    Vojnosanit Pregl; 2001; 58(2):131-6. PubMed ID: 11475664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modification of the incidence and course of CMV infections following kidney transplantation by passive immunization--initial experiences with a hyperimmunoglobulin].
    Hoyer J; Dennin RH; Schulz E
    Immun Infekt; 1985 Nov; 13(6):285-9. PubMed ID: 3000921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease.
    Snydman DR
    Rev Infect Dis; 1990; 12 Suppl 7():S839-48. PubMed ID: 2173113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cytomegalovirus infection after organ transplantation with passive immunization. An analysis of 6 randomized clinical trials.
    Metselaar H; Weimar W
    Beitr Infusionsther; 1992; 30():198-202. PubMed ID: 1284706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in cytomegalovirus prevention and management.
    Snydman DR; Rubin RH; Werner BG
    Am J Kidney Dis; 1993 Feb; 21(2):217-28. PubMed ID: 8381578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.